SGS Expands Testing Capabilities at Its Glasgow Facility
SGS announces expansion of cell bank and bulk harvest testing services.
Analytical contract service provider SGS announced expanded capabilities and capacity for testing cell banks and routine bulk harvest for vaccines, gene and cell therapies, monoclonal antibodies, and other recombinant protein-based biological medicines at the company’s Glasgow, UK facility.
The £7.6-million ($10-million) investment, supported in part by a Scottish Enterprise Research and Development grant award of £1.7 million ($2.2 million), was announced in a company statement on Jan. 29, 2019.
The investment includes an additional 1200 sq. m. of space, bringing the total to 2400 sq. m. Additional scientific and quality personnel will be hired, the company reported.
The new laboratory will increase the company’s capacity for existing biosafety services and enhanced real-time polymerase chain reaction platforms and SGS will develop and validate cell-based viral detection systems at the site.
Source: SGS
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
